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Table 1. Correlation between laboratory parameters and categorical outcomes
Parameter (units) median, [range] CRP (mg/L) C3 (mg/dL) (mg/dL) IgG (mg/dL) HGB (g/dL) Lymph (K/uL) Platelets (K/uL)
Intensity of immunosuppression
none/mild (n549) 0.73 [0.3-44] 129 [66-179] 24 [15-37] 887 [200-3380] 13.3 [10.7-17.1] 1.63 [0.34-7.55] n.s.*
moderate (n571) 0.69 [0.15-41.6] 128 [64-210] 27 [13-61] 570 [98-2190] 12.5 [8.2-16.1] 1.22 [0.11-5.00] n.s.
high (n569) 1.22 [0.3-58.9] 147 [76-216] 31 [13-74] 580 [142-2050] 12.3 [8.9-16.2] 1.00 [0.15-5.30] n.s.
p-value 0.008 0.0046 0.0011 0.002 0.0006 0.011
Activity by therapeutic intent
non active (n584) 0.61 [0.15-44.3] 126 [64-210] 24 [13-74] n.s. n.s. n.s. 223 [33-465]
active (n571) 1.73 [0.3-58.9] 145 [76-216] 31 [15-68] n.s. n.s. n.s. 278 [56-648]
p-value <0.0001 0.0003 0.0004 0.012
NIH global severity stage
moderate (n562) 0.62 [0.15-27] 122 [66-187] n.s. n.s. n.s. n.s. 214 [33-461]
severe (n5125) 1.15 [0.26-58.9] 139 [64-216] n.s. n.s. n.s. n.s. 265 [34-648]
p-value <0.0001 0.0017 n.s. n.s. n.s. n.s. 0.0028
*Not significant.
Poster Session II S341inflammation and cGvHD severity and activity we analyzed a large
prospective patient cohort.
Methods: 189 adults were enrolled onto the NCI cross-sectional
cGvHD natural history study between 2004-2010. 33% had moder-
ate and 66% had severe cGvHD per NIH criteria (88% classic, 12%
overlap). 80% were receiving systemic immunosuppression and
failed a median of 4 (range 0-9) prior therapies (PST). Median fol-
low-up of survivors was 30.3 months (1-70). Laboratory predictors
included: CRP, ferritin, complement, albumin, IgG, b-2 microglo-
bulin, total protein, PTH (parathyroid hormone), ESR, CBC and
platelets. cGvHD severity outcomes included: NIH global stage
(moderate vs. severe), NIH average organ score, Lee symptom scale,
SF36 physical scale, Schirmer’s tear test, Schubert oral mucositis
scale (OMRS), skin body surface area (BSA) as continuous outcomes.
cGvHD activity outcomes (categorical) included: intensity of immu-
nosuppression (none/mild, moderate, high), clinician’s global assess-
ment (CGA) of change (7-point scale) and active vs. non active based
on therapeutic intent at enrollment.
Results: Correlation between continuous outcomes and laboratory
parameters was weak. Significant univariate analysis results related
to categorical outcomes are shown in the Table. By multivariable
logistic regression analysis taking into consideration clinical, demo-
graphic and laboratory parameters, lower albumin (p \ 0.0001),
higher platelets (p 5 0.045) and higher number of PST (p \
0.0001) were associated with active disease (identifying 75%of active
and 77% of non-active cases). Similarly, higher platelets (p5 0.021),
higher number of PST (p\ 0.0001) and lower FEV1 (p\ 0.0001)
were associated with severe disease (identifying 76% of severe and
74% of moderate cases). Only higher absolute lymphocytes (p 5
0.019), higher IgG (p5 0.0054) and lower PTH (p5 0.045) were as-
sociated with better survival in univariate analysis.
Conclusion: Some common laboratory indicators of inflammation
can serve as markers of active and severe cGvHD. Better understand-
ing of biologic mechanisms influencing these markers may lead to
deciphering the biology of cGVHD and designing therapeutic
approaches.525
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Introduction: Dendritic cells (DC) are centrally involved in the
development of acute graft-versus-host disease (GvHD) following
allogeneic hematopoietic cell transplantation (alloHCT). We pre-
viously showed that the activation status, as assessed by CMRF-44 antigen expression, of blood CD11c+ myeloid DC is highly
associated with the severity of acute GvHD, and that activated
DC may be detected in the circulation prior to clinical presentation
of GvHD (Transplantation 2007;83: 839–846). We also reported
that there was also a positive correlation between aGVHD and
the expression of the chemokine receptor CCR5 on myeloid DC
(Blood, 114,Suppl.:2251,2009). Because of the phenotypic and
functional heterogeneity of the CD11c+ DC population, we further
investigated the precise nature of the CD11c+ DC subset express-
ing CCR5 in the peripheral blood in 24 patients post alloHCT, and
correlated the findings with GVHD outcomes.
Methods: Peripheral blood was collected twice weekly up to day 100
post transplant from 24 alloHCT patients. The expression of CCR5
receptor on CD11c+ and CD11c- DC subsets was evaluated using
multiparameter flow cytometry.
Results: Eleven of 24 patients developed acute GvHD (4 grade I, 7
grades II-IV), the remaining 13 patients had no GvHD. The per-
centage of CD11c++ CD16+ DC expressing CCR5 correlated with
the development of acute GvHD grades II-IV. The maximum
CCR5 expression detected onCD11c+CD16+DC in patients devel-
oping grade II-IV GvHD (mean 36.0 +/2 6.9%, n 5 7)was higher
than in those with grade 0-I GvHD (17.2 +/2 3.2 %, n 5 17) (p 5
0.0153), and occurred prior to the clinical onset of GVHD in 6 of
8 patients with CCR5 levels . 20%. Levels of expression of CCR5
on other DC subsets, including CD16- CD11C+ DC, were not
preditive for GVHD.
Conclusion: Expression of CCR5 on circulating CD11c+ CD16+
myeloid DC post allo-HCT correlates with the development of
moderate to severe GvHD. This observation may indicate altered
homing patterns of these cells during the alloimuune response.
Detection of raised numbers of CCR5+ CD11c+ CD16+ DC could
allow earlier therapeutic intervention prior to the development of
clinical GVHD, if these findings are confirmed in a larger study.526
IMPAIRED THYMOPOIESIS WITH NORMAL T REGULATORY CELL NUM-
BERS IS ASSOCIATEDWITH SEVERE CHRONIC GRAFT-VERSUS-HOST DIS-
EASE
Buxbaum, N.P.1, Williams, K.M.2, Treadwell, S.2, Amarnath, S.2,
Eckhaus, M.3, Gress, R.E.2 1National Institutes of Health, Bethesda,
MD; 2National Institutes of Health, Bethesda, MD; 3National Institutes
of Health, Bethesda, MD
Chronic GVHD (cGVHD) is a significant complication of alloge-
neic hematopoietic stem cell transplantation (AHSCT). Although T
cells have been implicated in cGVHD pathobiology, the role of the
thymus in this process has yet to be defined. We characterized
thymus and spleen T cell subsets in a murine model of cGVHD to
elucidate the role of the thymus in this process. The murine model
of minor-histocompatibility mismatch cGVHD, B10.D2- .
BALB/c, was validated by pathologic review that correlated with
the clinical scoring and showed cGVHDpathology in skin, stomach,
